Liraglutide injection

The second application for listing of liraglutide injection in China

Liraglutide is a human glucagon like peptide-1 (GLP-1) analog, which has 97% sequence homology with human GLP-1. The first original product was developed by Novo Nordisk Nordisk, and was approved to control blood sugar in adult type 2 diabetes patients. Liraglutide not only effectively controls blood sugar, but also has cardiovascular protection and weight loss effects. Its weight loss indications have been approved by the US FDA.

Indications:

Liraglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.